IO BIOTECH INC. - COM

IO Biotech to Participate in March 2023 Investor Conferences

22 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Appointment of Devin Smith as General Counsel

23 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

IO Biotech Provides Business Update

09 Jan 2023 07:05:46 By Nasdaq GlobeNewswire

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

09 Nov 2022 16:08:30 By Nasdaq GlobeNewswire

IO Biotech Announces Third Quarter Results for 2022

09 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors

03 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

IO Biotech to Participate in the Jefferies London Healthcare Conference

31 Oct 2022 08:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Appointment of New Chief Financial Officer

13 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

IO Biotech Announces Second Quarter Results for 2022

11 Aug 2022 17:00:18 By Nasdaq GlobeNewswire

IO Biotech to Participate in the 2022 BIO International Convention

06 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

26 May 2022 17:00:00 By Nasdaq GlobeNewswire

IO Biotech to Participate in the Jefferies Healthcare Conference

23 May 2022 08:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

18 May 2022 07:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces First Quarter Results for 2022

16 May 2022 16:15:00 By Nasdaq GlobeNewswire

IO Biotech Hosting Key Opinion Leader Webinar Series

22 Apr 2022 08:33:34 By Nasdaq GlobeNewswire

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

12 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

08 Apr 2022 16:15:00 By Nasdaq GlobeNewswire

IO Biotech Announces Year-End Results for 2021

31 Mar 2022 16:15:00 By Nasdaq GlobeNewswire